A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation

Bioorg Med Chem. 2005 Oct 15;13(20):5700-9. doi: 10.1016/j.bmc.2005.06.008.

Abstract

A cyclic molecule 1 constituted by a hepta-peptide nucleic acid sequence complementary to the apical loop of domain IV of hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA has been prepared via a 'mixed' liquid-phase strategy, which relies on easily available protected PNA and poly(2-aminoethylglycinamide) building blocks. This compound 1 has been elaborated to mimic 'loop-loop' interactions. For comparison, its linear analog has also been investigated. Although preliminary biological assays have revealed the ability of 1 to inhibit in vitro the HCV IRES-dependent translation in a dose-dependent manner, the linear analog has shown a slightly higher activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hepacivirus / genetics*
  • In Vitro Techniques
  • Magnetic Resonance Spectroscopy
  • Models, Molecular
  • Peptide Nucleic Acids / chemistry
  • Peptide Nucleic Acids / drug effects*
  • Protein Biosynthesis*
  • RNA, Viral / physiology*
  • Ribosomes / chemistry*
  • Spectrometry, Mass, Electrospray Ionization

Substances

  • Peptide Nucleic Acids
  • RNA, Viral